Can compensatory hyperinsulinemia occur in early insulin resistance even when fasting glucose is normal?

The physiological phenomenon of compensatory hyperinsulinemia is a well-documented precursor to overt metabolic dysfunction, often occurring years before clinical hyperglycemia develops. In early-stage insulin resistance, the body’s homeostatic mechanisms prioritize maintaining normal glucose concentrations even at the cost of significantly elevated insulin levels.

Clinical evidence and mechanisms

In the early stages of metabolic dysfunction, peripheral tissues—specifically skeletal muscle and the liver—exhibit a reduced response to insulin. To prevent a rise in blood glucose, the pancreatic beta-cells initiate a compensatory response.

• Beta-cell adaptation: Compensation involves increasing the insulin secretion rate (ISR) and expanding beta-cell mass. This is driven by mechanisms such as the upregulation of glucokinase activity and GLUT-2 transporters, which lowers the threshold for insulin release.
• Insulin clearance: Beyond increased secretion, there is often a concomitant decrease in insulin clearance rates (ICR) by the liver, further elevating systemic insulin concentrations to overcome tissue resistance.
• Glucose maintenance: This robust adaptation allows individuals to maintain euglycemia (fasting glucose typically <100 mg/dL) despite underlying resistance. Research utilizing the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) frequently identifies individuals with scores ≥2.0–2.5 (indicating resistance) who still present with clinically "normal" fasting glucose.

Pathophysiological implications

While effective in the short term, this hyperinsulinemic state indicates significant beta-cell strain.

• Progression: Persistent hyperinsulinemia can eventually lead to beta-cell exhaustion or "failure," at which point insulin production can no longer compensate for resistance, leading to impaired glucose tolerance and type 2 diabetes.
• Diagnostic nuances: Because standard clinical screenings often focus solely on fasting glucose or HbA1c, this early stage of insulin resistance is frequently missed. Identifying elevated fasting insulin or a high HOMA-IR score is necessary to detect this compensatory phase.

Bottom line

Compensatory hyperinsulinemia is a recognized physiological hallmark of early insulin resistance. It functions as a successful but taxing adaptation that maintains normal fasting glucose levels through increased pancreatic output and reduced hepatic clearance.